GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Yichang HEC ChangJiang Pharmaceutical Co Ltd (HKSE:01558) » Definitions » Cash And Cash Equivalents

Yichang HEC ChangJiang Pharmaceutical Co (HKSE:01558) Cash And Cash Equivalents : HK$1,831 Mil (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Yichang HEC ChangJiang Pharmaceutical Co Cash And Cash Equivalents?

Yichang HEC ChangJiang Pharmaceutical Co's quarterly cash and cash equivalents increased from Dec. 2022 (HK$1,031.33 Mil) to Jun. 2023 (HK$4,136.25 Mil) but then stayed the same from Jun. 2023 (HK$4,136.25 Mil) to Dec. 2023 (HK$1,831.44 Mil).

Yichang HEC ChangJiang Pharmaceutical Co's annual cash and cash equivalents declined from Dec. 2021 (HK$1,385.02 Mil) to Dec. 2022 (HK$1,031.33 Mil) but then increased from Dec. 2022 (HK$1,031.33 Mil) to Dec. 2023 (HK$1,831.44 Mil).


Yichang HEC ChangJiang Pharmaceutical Co Cash And Cash Equivalents Historical Data

The historical data trend for Yichang HEC ChangJiang Pharmaceutical Co's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yichang HEC ChangJiang Pharmaceutical Co Cash And Cash Equivalents Chart

Yichang HEC ChangJiang Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash And Cash Equivalents
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,092.49 2,424.17 1,385.02 1,031.33 1,831.44

Yichang HEC ChangJiang Pharmaceutical Co Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,385.02 1,007.03 1,031.33 4,136.25 1,831.44

Yichang HEC ChangJiang Pharmaceutical Co Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.


Yichang HEC ChangJiang Pharmaceutical Co  (HKSE:01558) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


Yichang HEC ChangJiang Pharmaceutical Co Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Yichang HEC ChangJiang Pharmaceutical Co's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.


Yichang HEC ChangJiang Pharmaceutical Co (HKSE:01558) Business Description

Traded in Other Exchanges
N/A
Address
No. 38 Binjiang Road, Yidu, Hubei Province, Yichang, CHN
Yichang HEC ChangJiang Pharmaceutical Co Ltd functions in the Chinese drug industry. As a domestic manufacturing wing of the HEC Group, Yichang employs its therapeutic technology to address viral, endocrine, metabolic, and cardiovascular diseases. The company's key revenue driver is the anti-viral product division, which manufactures its key product, Kewei. It is one of the leading products in China's anti-influenza market. Its other products include Ertongshu, Oumeining, Olmesartan Tablets, and Clarithromycin Tablets.
Executives
Shao Guan Xin Yu Neng Shi Ye Tou Zi You Xian Gong Si 2201 Interest of corporation controlled by you
Xiang Gang Dong Yang Guang Xiao Shou You Xian Gong Si 2101 Beneficial owner
Shen Zhen Shi Dong Yang Guang Shi Ye Fa Zhan You Xian Gong Si 2201 Interest of corporation controlled by you
Guang Dong Dong Yang Guang Yao Ye Gu Fen You Xian Gong Si 2101 Beneficial owner
Ru Yuan Yao Zu Zi Zhi Xian Xin Jing Ke Ji Fa Zhan You Xian Gong Si 2201 Interest of corporation controlled by you
Ru Yuan Yao Zu Zi Zhi Xian Yu Neng Dian Zi Shi Ye You Xian Gong Si 2201 Interest of corporation controlled by you
Guo Meilan 2201 Interest of corporation controlled by you
Hua Xiaoyi 2201 Interest of corporation controlled by you
Zhang Yushuai 2201 Interest of corporation controlled by you
Blackstone Dawn Pte. Ltd. 2101 Beneficial owner
Blackstone Tactical Opportunities Management Associates (cayman) – Nq L.p. 2201 Interest of corporation controlled by you
Blackstone Inc. 2201 Interest of corporation controlled by you
Btof (dawn Feeder) (cayman) – Nq L.p. 2201 Interest of corporation controlled by you
Blackstone Tactical Opportunities Management Associates Iii (cayman) – Nq L.p. 2201 Interest of corporation controlled by you
Blackstone Tactical Opportunities Lr Associates (cayman) – Nq Ltd. 2201 Interest of corporation controlled by you

Yichang HEC ChangJiang Pharmaceutical Co (HKSE:01558) Headlines

No Headlines